Difference between revisions of "Stem cell decisions"
Jump to navigation
Jump to search
(An emerging concept of major questions doctrine might rein in FDA over-regulation in this field.) |
|||
| Line 5: | Line 5: | ||
(add to this list) | (add to this list) | ||
| + | An emerging concept of [[major questions doctrine]] might rein in [[FDA]] over-regulation in this field. | ||
== See also == | == See also == | ||
*[[Stem cell statutes]] | *[[Stem cell statutes]] | ||
*[[Stem cell regulations]] | *[[Stem cell regulations]] | ||
[[category:stem cells]] | [[category:stem cells]] | ||
Revision as of 05:07, April 26, 2023
Stem cell decisions include this growing list:
- United States v. Cal. Stem Cell Treatment Ctr., No. EDCV 18-1005 JGB (KKx), 2022 U.S. Dist. LEXIS 156714 (C.D. Cal. Aug. 30, 2022) (ruling against the FDA in its attempt to stop stem cell treatments at a clinic in California)
- Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341, 351 n.5, 121 S. Ct. 1012, 148 L. Ed. 2d 854 (2001) (Congress rejected in its authorization of the FDA "any intent to directly regulate the practice of medicine.")
(add to this list)
An emerging concept of major questions doctrine might rein in FDA over-regulation in this field.